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Abstract
In this study, a pyrosequencing method for monitoring two genes related to isoniazid (INH)-resistance and a region of the rpoB gene
linked to rifampin (RMP)-resistance in Mycobacterium tuberculosis was developed and evaluated. Speciﬁcally, a 20-base pair (bp) region of
inhA (from )24 to )4), a 35-bp region of ahpC (from )39 to )4), and a 57-bp region of rpoB (from codon 515 to 533) were analysed
by pyrosequencing. For the development of the method, selected non-consecutive clinical isolates of M. tuberculosis were analysed,
including: 25 isolates susceptible to both INH and RMP, 18 RMP-monoresistant isolates, 17 INH-monoresistant isolates, and 15 multi-
drug-resistant strains. Our pyrosequencing methodology was further evaluated using 96 M. tuberculosis isolates. Mutations in ahpC were
found to be associated with INH resistance (p <0.05). By setting any mutation in ahpC as a marker of resistance, the speciﬁcity and the
positive predictive value (PPV) were 100%. Similarly, any mutation in the rpoB gene was associated with a RMP resistance phenotype
(p <0.01). Using any mutation in rpoB as a marker of RMP resistance, the sensitivity of this assay was 73% and the speciﬁcity and PPV
were 100%. The use of this pyrosequencing method to analyse the ahpC and rpoB genes allowed us to detect INH- and/or RMP-resis-
tant isolates. Furthermore, this method represents an opportunity to expedite the description of novel mutations related to drug resis-
tance.
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For the effective control of TB, both identiﬁcation of Mycobac-
terium tuberculosis and detection of drug resistance in M. tuber-
culosis are needed [1,2]. Using conventional methodologies, a
minimum of 3–8 weeks is needed to detect drug-resistant
strains [3–5]. However, more rapid results can be achieved by
testing clinical isolates using molecular methods [6,7].
Previous reports indicate that >95% of all rifampin
(RMP)-resistant strains have a mutation present within a
RMP resistance-determining region (RRDR) of 81 base pairs
(bp) located in the rpoB gene [8]. In contrast, resistance to
isoniazid (INH) has been associated with various mutations
in several genes. For example, 50–95% of INH-resistant
strains are the result of mutations in codon 315 of the katG
gene [9–11], 20–35% of INH-resistant strains have muta-
tions in the inhA gene [10–12,], and 10–15% of INH-resis-
tant strains have mutations in the ahpC-oxyR intergenic
region [11–13].
To detect M. tuberculosis resistance, several molecular
methods have been developed to identify mutations in the
rpoB and katG genes [8,14–16]. These methods largely
involve detection of single nucleotide polymorphisms, which
limits the scope of these methods. Pyrosequencing is a
real-time sequencing technique that is fast, reliable and cost-
effective.
Our objective was to develop and evaluate a method for
the molecular monitoring of two regions related to INH resis-
tance in the inhA and ahpC genes, as well as in a separate region
related to RMP resistance in the rpoB gene, in clinical isolates
of M. tuberculosis, using the pyrosequencing method.
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All strains were isolated from decontaminated sputum
or bronchial washing specimens, cultured at 37C on
Lo¨wenstein–Jensen media and identiﬁed by traditional bio-
chemical tests [5]. For the development of the assay, 75
non-consecutive clinical isolates were selected according to
susceptibility results from the Centro Regional de Control
de Enfermedades Infecciosas, Universidad Auto´noma de Nu-
evo Leo´n and from the Laboratorio Estatal de Salud Pu´blica,
in the state of Nuevo Leon during a period of 1 year.
Twenty-ﬁve strains were susceptible to both INH and RMP,
18 were RMP-monoresistant, 17 were INH-monoresistant,
and 15 strains were resistant to both RMP and INH, repre-
senting multidrug-resistant strains. For evaluation of the
method, 96 clinical isolates of M. tuberculosis were collected
consecutively in the Tamaulipas state of Mexico from the
Hospital General de Reynosa (47% of clinical isolates) and
the Health Jurisdiction IV, Reynosa (53% of strains). Only
one isolate per patient was included. Mycobacterium tuberculo-
sis reference strains, H37Rv and H37Ra, were used as
controls.
Drug susceptibility
Drug-susceptibility testing was performed according to the
protocol of the WHO [3,4] and using the standard propor-
tion method [5]. All selected strains exhibited the same phe-
notypic drug-resistance pattern in both drug-susceptibility
assays.
Isolation of DNA
Bacterial cells were harvested from Lo¨wenstein–Jensen med-
ium, mixed with 1 mL of 50 mM Tris–HCl (pH 8.0) and inac-
tivated for 60 min at 85C. Suspension was incubated with
lysozyme (1 mg/L) at 37C for 2 h followed by incubation
with 1% SDS and proteinase K (0.4 mg/L) at 55C for 1 h.
DNA was extracted using a phenol extraction, ethanol pre-
cipitation method.
PCR
Primers for ampliﬁcation of the inhA, ahpC and rpoB genes
were designed using BEACON DESIGNER 4.0 (PREMIER Biosoft
International, Palo Alto, CA, USA) (Table 1). Sequencing
primers were designed using http://www.pyrosequencing.com
(Table 1). Ampliﬁcations were performed in a ﬁnal volume of
50 lL that contained 1· PCR buffer, 2 mM MgCl2, 0.2 mM
of each dNTP, 200 nM of each primer, 1 U of AmpliTaq
polymerase (Bioline USA Inc., Randolph, MA, USA) and
200 ng of DNA. The thermocycling conditions were: 94C
for 3 min, 45 cycles of 30 s at 94C, 30 s at 50C, and 30 s
at 72C, followed by 72C for 5 min.
Pyrosequencing analysis
Preparation of template and sequencing reactions were per-
formed according to the manufacturer’s directions (Biotage
AB, Uppsala, Sweden). Real-time pyrosequencing was per-
formed in an automated 96-well pyrosequencer. A 20-bp
region of inhA ()24 to )4) and a 35-bp region for ahpC ()39
to )4) were sequenced. For rpoB, a 57-bp region within the
RRDR was sequenced (from codon 515 to 533) with three
sequencing reactions using PCR products generated with the
same forward and reverse primers and sequencing primers 1,
2 and 3. The ﬁrst reaction sequenced codons 515–526, the
second reaction sequenced codons 526–531, and the third
reaction sequenced codons 531–533. Mutations detected in
ahpC and inhA genes in both the development and evaluation
of the assay were conﬁrmed in each DNA sample by conven-
tional sequencing methods. These analyses were performed
at the Instituto de Biotecnologı´a de la Universidad Nacional
Auto´noma de Me´xico.
Analysis of data
The v2 test or Fisher’s exact test was used to evaluate the
association of any mutation or mutations with a drug-resis-
tance phenotype. All statistical tests were two-tailed and
performed with a level of signiﬁcance of 0.05. The CIs were
two-sided with 95% CI. The SPSS 10.0 statistical package was
used for all calculations (SPSS Inc., Chicago, IL, USA). Diag-
nostic performance was calculated for each mutation identi-
ﬁed as a marker of drug resistance using phenotypic
screening methods as a reference standard. Corresponding
95% CIs were also calculated. For evaluation of the method,
concordance and j coefﬁcients were calculated.
TABLE 1. Primers used in this study and the lengths of the
resulting PCR products
Drug Gene Primer Sequence (5¢ ﬁ 3¢)
Product
(bp)
INH inhA Forward B-GAGCGTAACCCCAGTGCGAAAG 162
Reverse CCAGGACTGAACGGGATACGAATG
Sequencing TGGCAGTCACCCC
ahpC Forward B-CGGCACTGCTGAACCACTG 184
Reverse CCTCATCATCAAAGCGGACAATG
Sequencing CATTTGGTTGCGACAT
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Results
Assay development
Pyrograms were interpreted and mutations detected using
both peak height and sequence output. Examples are shown
in Figs 1 and 2.
Data from non-consecutive selected strains (n = 75) analy-
sed by pyrosequencing showed that among the RMP-mono-
resistant isolates, 9/18 strains presented mutations in codon
531 or 533 of the rpoB gene (Table 2). For the INH-monore-
sistant isolates, 13/17 did not contain mutations in the
regions analysed.
Mutations in the ahpC gene were associated with INH
resistance (p <0.05) and when any mutation in the ahpC gene
was considered a marker of INH resistance, the speciﬁcity
and positive predictive value (PPV) were 100% (95% CI 100–
100). Similarly, the presence of a mutation in the rpoB gene
was associated with a RMP resistance phenotype (p <0.01).
When any mutation in the rpoB gene was considered as an
indicator of resistance, the sensitivity of the pyrosequencing
method was determined to be 73% (95% CI 58–88), the
speciﬁcity and PPV were 100% (95% CI 100–100) and the
diagnostic accuracy was 88% (95% CI 81–95).
Method evaluation
To evaluate the pyrosequencing method, 96 consecutive clin-
ical isolates were analysed (Table 3). For the rpoB gene, the
application of the method in 96 consecutive samples had a
concordance of 69% between the results in the phenotypic
and the pyrosequencing method (j = 0.692).
Discussion
The method we describe here to detect RMP resistance
had a sensitivity of 73%, a speciﬁcity and PPV of 100%,
and a diagnostic accuracy of 88%. Given the PPV
observed, this method proved to be a useful tool for the




FIG. 1. Representative pyrosequencing analyses of the ahpC gene.
Sequencing pyrograms of (a) Mycobacterium tuberculosis, wild type;
(b) the same region of ahpC in an isolate containing a )32 G ﬁ A
substitution. Pyrograms show the complementary sequence.
(a)
(b)
FIG. 2. Representative pyrosequencing analyses of the inhA gene.
Sequencing programs of (a) Mycobacterium tuberculosis, wild type;
(b) the same region of inhA in an isolate containing a )15C ﬁ T
substitution. Pyrograms show the complementary sequence.
CMI Garza-Gonza´lez et al. Molecular monitoring of M. tuberculosis drug-resistance 609
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 607–612
The ahpC gene is not the primary target associated with
INH resistance and for this reason the sensitivity is
expected to be low. This fact renders this statistical deter-
mination clinically useless. For this reason, we focused on
the determination of the speciﬁcity and PPV of this gene as
a marker of resistance. Our data also conﬁrmed that muta-
tions in the ahpC gene correlate with INH resistance
(p <0.05) [17–19]. These mutations were associated with an
assay speciﬁcity and PPV of 100%, which may be clinically
useful once a mutation is detected. The low prevalence of
mutations associated with INH resistance detected in this
study parallels the low prevalence of INH-resistant cases
identiﬁed throughout the world. In the populations studied
for the development of this assay, mutations in codon 315
of the katG gene represented between 53.7% [20] and
67.6% [21] of all INH-resistant strains identiﬁed. This repre-
sents >30% of INH-resistant strains with the codon 315
mutation detected in the katG gene. Therefore, our results
emphasize the importance of studying genes related to INH
resistance other than katG.
Previous reports have described the application of pyrose-
quencing to the identiﬁcation of RMP-resistant M. tuberculosis
isolates [22–26]. The advantage of the method described
here compared with previous studies is the possibility of
including molecular monitoring as well as analysis of speciﬁc
mutations. This is supported by the fact that in the evalua-
tion phase, this method was able to detect mutations that
were not present in the development of the assay. These
mutations were both in the rpoB (CAG ﬁ CAA mutation in
codon 517, and GAC ﬁ GTC transition in codon 516) and
inhA ()15 C ﬁ T) genes.
In the analysis of all strains [n = 171: development
(n = 75) plus evaluations (n = 96)], the most frequent site
for mutations in M. tuberculosis strains was in codon 531 of
the rpoB gene (in 18 out of 41 resistant strains).
The two base pair substitutions at this codon were
TCG ﬁ TTG and TCG ﬁ TGG. The second most common
site for mutations was in codon 526, where the wild-type
CAC codon was replaced by either TGC, GAC or CGC (in
nine out of 41 resistant strains). The high frequency of muta-
TABLE 2. Resistance patterns of Mycobacterium tuberculosis isolates and mutations detected by pyrosequencing during devel-
opment of the method
N (%) of strains Rifampin Isoniazid rpoB 526 rpoB 531 rpoB 533 ahpC
25 (33.3) Susceptible Susceptible None None None None
9 (12) Resistant Susceptible None None None None
6 (8) Resistant Susceptible None TCG ﬁ TTG None None
2 (2.7) Resistant Susceptible None TCG ﬁ TGG None None
1 (1.3) Resistant Susceptible None None CTG ﬁ CCG None
13 (17.4) Susceptible Resistant None None None None
3 (4) Susceptible Resistant None None None )32 G ﬁ A
1 (1.3) Susceptible Resistant None None None )39 C ﬁ T
3 (4) Resistant Resistant None TCG ﬁ TTG None None
1 (1.3) Resistant Resistant CAC ﬁ CGC None None None
1 (1.3) Resistant Resistant CAC ﬁ TGC None None None
2 (2.7) Resistant Resistant CAC ﬁ GAC None None None
1 (1.3) Resistant Resistant CAC ﬁ GAC None None )10 C ﬁ T
7 (9.3) Resistant Resistant None TCG ﬁ TTG None None
Regions monitored: 57 bp of rpoB (from codon 515 to 533), 35 bp of ahpC (from )39 to )4), and 20 bp of inhA (from )24 to )4). No mutations were detected in the inhA
region monitored.
TABLE 3. Resistance patterns of Mycobacterium tuberculosis isolates and mutations detected by pyrosequencing during evalua-
tion of the method
N (%) of strains Rifampin Isoniazid rpoB 516 rpoB 517 rpoB 526 ahpC inhA
75 (78.1) Susceptible Susceptible None None None None None
1 (1) Susceptible Susceptible None None None None )15 C ﬁ T
1 (1) Susceptible Susceptible None None None )32G ﬁ A None
9 (9.4) Susceptible Resistant None None None None None
1 (1) Susceptible Resistant None None None None )15 C ﬁ T
1 (1) Susceptible Resistant None CAG ﬁ CAA None None None
3 (3) Resistant Susceptible None None None None None
3 (3) Resistant Susceptible None None CAC ﬁ CGC None None
1 (1) Resistant Resistant GAC ﬁ GTC None CAC ﬁ CGC None None
1 (1) Resistant Resistant GAC ﬁ GTC None None None None
Regions monitored: 57 bp of rpoB (from codon 515 to 533), 35 bp of ahpC (from )39 to )4), and 20 bp of inhA (from )24 to )4). No mutations were detected within co-
dons 531 and 533 of the rpoB gene.
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tion at codon 531 in RMP-resistant strains, especially the
TGC ﬁ TTG substitution, is consistent with other reports
that have analysed the same region in a variety of popula-
tions [11,15,16]. In contrast, no mutations were detected in
12 of the 41 RMP-resistant strains analysed. We hypothesize
that for this subset of isolates, the mutations associated with
RMP resistance are present either in the RRDR region not
monitored in this study (codon 507–514), outside the RRDR,
or in other genes. The role of unknown mechanisms in drug
resistance, independent of or in conjunction with genetic
mutations, cannot be excluded. Additional data extracted
from the analysis of all 171 strains showed a correlation link-
ing mutations in ahpC and inhA with resistance to INH
(p <0.01).
It has been reported that 8–20% of INH-resistant
M. tuberculosis isolates have mutations in the inhA promoter
region [10,17]. In this study, we found a lower prevalence
of mutations in the inhA gene, with only two strains identi-
ﬁed with the )15C ﬁ T mutation, one in an INH-suscepti-
ble strain and the other in an INH-resistant strain. These
data strongly suggest that, in the strains studied, this muta-
tion does not appear to play an important role in deter-
mining INH resistance. Similarly, for an rpoB CAG517-CAA
mutation detected in only one INH monoresistant strain, in
which both codons code for Gln, the mutation is consid-
ered to be silent. Moreover, the silent mutation at the
Gln-517 codon of the rpoB gene has been previously
described [27]. Our method has proved capable of detect-
ing silent mutations and distinguishing them from mutations
that may be related to drug resistance. This is in contrast
to some commercial kits, which deﬁne mutations by the
absence of the wild-type sequence.
Finally, our method was developed and evaluated using
clinical isolates from two northeastern border states of Mex-
ico: Tamaulipas, which has the second highest morbidity
rates in Mexico for TB (32.67/100 000), and Nuevo Leon,
which has a lower rate of TB (17.87/100 000) [28]. Analysis
of strains from these two states showed that isolates from
Nuevo Leon did not contain any mutations in codon 516 of
the rpoB gene, yet this mutation was detected in two clinical
strains from Tamaulipas. This result was expected due to the
low frequency of mutation reported for this codon (4.7%)
[22].
To our knowledge, this paper is the ﬁrst to provide a
pyrosequencing method for monitoring regions in the ahpC
and inhA genes in the search for mutations related to INH
resistance. In conclusion, the assay developed and validated
in this study was shown to be a useful tool for rapid detec-
tion of RMP- and INH-resistant M. tuberculosis strains and for
the identiﬁcation of associated novel mutations.
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